Florida is currently home to 3835 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Miami, Tampa, Jacksonville and Orlando. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Olorofim Aspergillus Infection Study
Recruiting
The purpose of this study is to compare treatment with olorofim versus treatment with AmBisome® followed by standard of care (SOC) in patients with IFD caused by proven IA or probable lower respiratory tract disease Aspergillus species (invasive aspergillosis, IA).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/26/2024
Locations: University of Florida, Gainesville, Florida
Conditions: Invasive Aspergillosis
Dynamic in Vivo PET Imaging and ex Vivo Biopsies From Skeletal Muscle and Adipose Tissue to Investigate the Effects of Exercise on Insulin Resistance and Mitochondrial Energetics in Type 2 Diabetes
Recruiting
The overall aim of this pilot study is to investigate the effects of exercise training on skeletal muscle and adipose tissue insulin resistance in subjects with Type 2 Diabetes (T2D).
Gender:
ALL
Ages:
Between 30 years and 65 years
Trial Updated:
09/26/2024
Locations: AdventHealth Translational Research Institute, Orlando, Florida
Conditions: Type 2 Diabetes
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies
Recruiting
This study is a Phase I/II, multicenter, first-in-human, open-label dose-escalation study of BT8009 given as a single agent and in combination with pembrolizumab in participants with advanced solid tumors associated with Nectin-4 expression or in participants with advanced solid tumor malignancies having renal insufficiency. The primary endpoints are: Dose limiting toxicities (Parts A-1 and A-2), Overall response rate per RECIST v1.1 (Parts B1-B7), Safety and tolerability (Parts B-8, B-9 and C),... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/26/2024
Locations: Ocala Oncology Center, Ocala, Florida
Conditions: Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Neoplasms, Ovarian Neoplasm, Hormone Receptor Positive, HER2-negative Neoplasms, Hormone Receptor Positive, HER2-low Neoplasms, Breast Neoplasms, Non-Small-Cell Lung Neoplasms
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
Recruiting
Gastroesophageal reflux disease (GERD) is caused by food or acid coming up from the stomach into the esophagus, repeatedly. The esophagus is the tube that carries food and liquids from the mouth to the stomach. The body uses stomach acid to break down food, but when acid rises up into the esophagus it can hurt or damage it. People with GERD often feel food coming back up into the throat and mouth and have a burning feeling in their stomach, chest, or throat, called heartburn. Other symptoms of G... Read More
Gender:
ALL
Ages:
Between 2 years and 11 years
Trial Updated:
09/25/2024
Locations: D&H National Research Centers, Miami, Florida
Conditions: Erosive Esophagitis
A Study of Radspherin® in Patients with Primary Advanced Epithelial Cancer, with Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
Recruiting
This is a Phase 2, controlled, randomised, parallel assignment, open label, multicentre study to evaluate efficacy and safety of a single intraperitoneal injection of Radspherin® in patients with primary advanced high-grade serous or high-grade endometrioid epithelial ovarian cancer, fallopian tube, or primary peritoneal cancer, with peritoneal metastasis that are HR proficient and scheduled to undergo NACT and IDS. The study will be conducted in 2 parts; first, a Safety Lead-in Cohort will be r... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/24/2024
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Peritoneal Carcinomatosis, Ovarian Cancer
A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions
Recruiting
The main aim is to evaluate the safety and tolerability of TAK-861 on participants with type 1 narcolepsy, who were exposed to previously tested doses of TAK-861.
Gender:
ALL
Ages:
Between 16 years and 70 years
Trial Updated:
09/24/2024
Locations: Florida Pediatric Research Institute, Orlando, Florida
Conditions: Narcolepsy Type 1
A Study to Evaluate Efficacy and Safety of Light Dose in Subjects with PWB Treated with Hemoporfin PDT
Recruiting
This is a multi-center, randomized, double-blind, vehicle-controlled, and sequential group Phase 2 study. Eligible subjects aged 18 to 65 years old with PWB of face and/or neck area (except subjects for Stage One) will receive Hemoporfin PDT or vehicle PDT in 8-week cycles at fixed drug dose (5 mg/kg) and different light fluence.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
09/24/2024
Locations: Skin and Cancer Associates (SCA) and the Center for Cosmetic Enhancement (CCE), Aventura, Florida
Conditions: Port-Wine Stain, Nevus Flammeus, Port-wine Birthmarks
Preventing Alzheimer's With Cognitive Training
Recruiting
Dementia is the most expensive medical condition in the US and increases in prevalence with age. More than 5 million Americans have Alzheimer's disease, the most common form of dementia. Mild cognitive impairment is a transitional stage between normal cognitive aging and Alzheimer's disease or another type of dementia, and is indicative of higher risk for dementia. In addition to the obvious health and quality-of-life ramifications of dementia, there are high direct (e.g., subsidizing residentia... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
09/24/2024
Locations: University of Florida, Gainesville, Florida
Conditions: Age-related Cognitive Decline, Alzheimer's Disease and Related Dementias
Non-Invasive Diagnosis of Pediatric Pulmonary Invasive Mold Infections
Recruiting
This study will establish a non-invasive diagnostic approach and evaluate clinical outcomes for children at high-risk for pulmonary invasive fungal infection (PIFI).
Gender:
ALL
Ages:
Between 120 days and 21 years
Trial Updated:
09/24/2024
Locations: All Children's Research Institute, Saint Petersburg, Florida
Conditions: Pulmonary Invasive Aspergillosis, Pulmonary Invasive Fungal Infections
Frataxin mRNA in Biofluids
Recruiting
The purpose of this research study is to determine a way to measure frataxin messenger RNA (mRNA) in fluids such as blood and cerebrospinal fluid (CSF) from patients with Friedreich's ataxia (FRDA). The gene mutation in FRDA leads to low levels of the mRNA and then low levels of the protein frataxin that leads to the disease. Treatments being developed for FRDA have the ability increase these levels including in brain where it is needed. Currently, there is no accepted way to measure frataxin pr... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
09/23/2024
Locations: University of Florida, Gainesville, Florida
Conditions: Friedreich Ataxia
Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients
Recruiting
The trial is an open-label randomized study that will examine whether switching to a selective IL23 inhibitor (guselkumab) is more effective than switching to a second TNFi (golimumab) among patients with PsA who have an inadequate response to a TNFi.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
09/23/2024
Locations: Family Arthritis Center, Loxahatchee Groves, Florida
Conditions: Psoriatic Arthritis
Assessing the Effect of Nicotine Reduction on ENDS User's Addiction and Exposures
Recruiting
The rapid increase of electronic nicotine delivery systems (ENDS) use by young people in the US and their potential to harm health, cause addiction, and serve as a risk for cigarette smoking or dual-use is alarming. The epidemic of ENDS use among young people in the US has been associated with the rise in popularity of ENDS products that are very efficient in delivering high doses of nicotine to users. Therefore, the investigators propose to study the effects of nicotine reduction (NR) on young... Read More
Gender:
ALL
Ages:
Between 21 years and 35 years
Trial Updated:
09/23/2024
Locations: Florida International University, Miami, Florida
Conditions: Electronic Cigarette Use